Kanuma ensuressurvival from Lysosomal Acid Lipse Deficiency; A Liver Disease
Alexion Pharmaceuticals, Inc. announced that the combined interim data from two ongoing open-label studies, VITAL and CL-08, show a 3-year...
GSK’S B vaccine prevents harmful disease among children; U.S FDA applauds
GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. FDA for its meningitis B vaccine Bexsero...
Janssen Pierce To Globally Collabrate With Theravance Biopharma For Oral, Pan-Jak Inhibitor Drug Candidate For The Treatment Of Inflammatory Bowel Disease
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today their entry into a worldwide collaboration with an affiliate of...
Roche’s TECENTRIQ®and Avastin® reduced the risk of disease worsening or death by 26 percent in certain advanced kidney cancer cases
Roche announced results from the positive Phase III IMmotion151 study of TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) as a first-line treatment...
Sanofi initiates Tender Offer for purchasing Bioverativ Inc
Sanofi announced that on February 7, 2018 it commenced a tender offer (the “Offer”) to acquire all of the outstanding...
Roche secure shares in tender offer for Ignyta, Inc
Roche and Ignyta, Inc. today announced that Roche’s wholly owned subsidiary Abingdon Acquisition Corp., has accepted for payment all shares...
Natural History of Diabetes
This editorial is a response to many and many requests to submit a paper on diabetes although I never treated...
Shire presentations at EAHAD 2018 demonstrate commitment to studying outcomes in patients with bleeding disorders
Shire plc , the global biotechnology leader in rare diseases, today announced the range of real-world and long-term research it...
Treatment and Management of Rare Lysosomal Diseases highlighted by shire at Global Conference
Shire plc the global biotechnology leader in rare diseases, today announced that it will have 12 presentations, including 11 posters...
Positive Results from the Pivotal Phase III ‘OPTIMISMM’ Study of POMALYST/IMNOVID
Celgene Corporation announced that the Phase III, randomized, open-label, international clinical study, OPTIMISMM, achieved its primary endpoint, showing a statistically...
About Us
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.